Ticker Scout
← tickerscout.ai

Eli Lilly and Company (LLY)

CIK 0000059478 · NYSE · Latest period: Q3 FY2026 (ended 2026-09-30, 10-Q accession 0000059478-26-000108) · Annual report: FY2025 10-K (filed 2026-02-12, accession 0000059478-26-000013) · Next expected filing: 10-K ~2027-02-11

PeriodQ3 FY2026Q2 FY2026Q1 FY2026

Published

MetricAmountvs. year ago
Revenue$24,397,000,000up 38.6%
Net income$6,451,000,000up 15.5%
Diluted EPS$7.22up 16.3%
Mounjaro revenue$10,723,000,000up 64.6%
Acquired IPR&D charges$4,181,000,000up 537.3%

Company details

NameELI LILLY & Co
TickerLLY
CIK0000059478
ExchangeNYSE
StateIndiana
IncorporationIndiana
SIC2834
OfficeLife Sciences
IndustryPharmaceutical Preparations
Latest period coveredQ3 FY2026, ended 2026-09-30, 10-Q, accession 0000059478-26-000108
Fiscal year end12/31 (MM/DD)
Next expected filing10-K around 2027-02-11 (predicted)

AI synthesis of four filings for Eli Lilly and Company

Sources: Form 10-K for the fiscal year ended December 31, 2025 (accession 0000059478-26-000013); Form 10-Q for the quarter ended September 30, 2026 (accession 0000059478-26-000108); third-quarter 2026 earnings release furnished on Form 8-K on October 29, 2026 (accession 0000059478-26-000104); and the May 2026 note-offering Form 8-K (accession 0001193125-26-232707). All amounts are in U.S. dollars, the company's reporting currency.


Business

From the FY2025 Form 10-K, accession 0000059478-26-000013.

Eli Lilly discovers, develops, manufactures, and sells prescription medicines, reporting as a single human-pharmaceutical segment. Most of its revenue now comes from the incretin franchise built on tirzepatide, Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea, which together were 56 percent of 2025 revenue; the rest comes from other cardiometabolic medicines and from oncology, immunology, and neuroscience brands. Products are sold in approximately 90 countries to wholesalers, pharmacy benefit managers, insurers, employers, governments, and hospitals; most revenue is net product revenue, with a smaller "collaboration and other" line made up of collaboration profit shares (chiefly Jardiance with Boehringer Ingelheim), royalties, and milestones. Lilly was incorporated in Indiana in 1901 and is headquartered in Indianapolis. At the end of 2025 it employed approximately 50,000 people, about 27,000 of them outside the U.S. and about 12,000 in research and development.

Therapeutic areas and marketed products. The 10-K groups its portfolio into four areas:

  • Cardiometabolic health, Mounjaro, Zepbound (its obesity indications are marketed under the Mounjaro name in various markets outside the U.S.), Trulicity, Jardiance (Boehringer Ingelheim collaboration, including Glyxambi, Synjardy, and Trijardy XR), Basaglar (Boehringer Ingelheim), and the Humalog and Humulin insulin families.
  • Oncology, Verzenio, Jaypirca, Retevmo, Inluriyo, Cyramza, Erbitux, and Tyvyt (Innovent collaboration, China).
  • Immunology, Taltz, Omvoh, Olumiant (Incyte collaboration), and Ebglyss (licensed from Roche and Genentech; Almirall holds European dermatology rights).
  • Neuroscience, Emgality and Kisunla.

How the money is made, and where gross-to-net bites. In the U.S. most products move through wholesalers; McKesson, Cencora, and Cardinal Health each accounted for a significant percentage of consolidated revenue in 2023, 2024, and 2025, and no other customer exceeded 10 percent. Rebates and discounts for managed care, Medicare, Medicaid, chargebacks, and patient-assistance programs are deducted from revenue at the time of sale and are the most judgment-heavy estimate in the accounts: a 5 percent change in the consolidated sales return, rebate, and discount liability at December 31, 2025 would have moved revenue by approximately $897 million, and about 87 percent of that liability related to U.S. sales. LillyDirect, the company's direct-to-patient digital platform, delivers select medicines dispensed by third-party pharmacies, and patient self-pay sales through it were a growing portion of the business in 2025; direct-to-employer channels are being built alongside it as a response to restrictive private-payer dynamics.

Competition and access. Lilly competes with multinational pharmaceutical, biotechnology, and generic companies and flags intensifying competition from China and other markets whose R&D capabilities have expanded, with companies there increasingly licensing assets to multinationals and competing directly. Coverage is a structural constraint on the obesity business: U.S. self-insured employers must generally opt in to cover anti-obesity medicines, and payers in various international markets do not cover them for weight loss at all. Counterfeit, misbranded, adulterated, and mass-compounded incretins remain a commercial and patient-safety problem, which the company says it will continue to fight, including through lawsuits where appropriate.

Intellectual property. Compound patents are the core protection, layered with regulatory data protection and, where granted, pediatric or orphan exclusivity. Selected estimated expiries from the 10-K:

ProductProtectionU.S.Major European countriesJapan
Mounjaro / Zepboundcompound patent203620372040
Mounjaro / Zepbounddata protection202720332030
Trulicitycompound patent202720292029
Jardiancecompound patent202920292030
Verzeniocompound patent203120332034
Taltzcompound patent203020312030
Emgalitycompound patent203320332035
Kisunlacompound patent203620362036
Jaypircacompound patent203720382040
Omvohcompound patent203720382039
Inluriyocompound patent203920392039
Cyramzacompound patent202620282026

Manufacturing. To meet expected incretin demand Lilly has undertaken a large capacity build, with new sites in North Carolina, Wisconsin, Indiana, Virginia, Texas, Alabama, Pennsylvania, Ireland, Germany, and the Netherlands. It also relies on contract manufacturers for portions of active-ingredient production, fill-finish, and device assembly, and, like the industry generally, on China-based suppliers for parts of its supply chain.

Pricing and policy environment at the time of the 10-K. In November 2025 Lilly announced preliminary voluntary agreements with the U.S. government: lower Medicaid and certain other drug prices, a more balanced launch-pricing approach across developed nations, expected Medicare access to discounted Lilly obesity medicines by July 1, 2026, an option for states to extend that access through Medicaid, and participation in a government direct-to-patient purchasing platform. The agreements also provide a three-year grace period during which Lilly products under a Section 232 investigation would not face tariffs, conditional on meeting U.S. manufacturing investment commitments. Under the Inflation Reduction Act, HHS selected Jardiance for a government-set Medicare price effective 2026 (a 66 percent discount to the 2023 list price for a 30-day supply) and, in January 2026, selected Trulicity and Verzenio for prices effective 2028.


Risk factors

Condensed from Item 1A of the FY2025 Form 10-K, accession 0000059478-26-000013. The September 2026 Form 10-Q (accession 0000059478-26-000108) reports no material changes to these risk factors.

Concentration in a few products, and in one product class. Mounjaro, Zepbound, Verzenio, Trulicity, Taltz, and Jardiance each generated more than $3 billion of revenue in 2025 and together accounted for 82 percent of total revenue; Mounjaro and Zepbound alone were 56 percent. Exclusivity loss, safety findings, demand or channel swings, access setbacks, or supply disruption in these products could materially affect results and, the filing says, could cause sudden declines or volatility in the stock price. A small number of U.S. wholesalers also concentrates credit and distribution risk.

R&D is costly and fails often. Candidates can fail late, after manufacturing capacity and launch inventory have been committed, so a significant portion of R&D spending will never earn a direct return. Lilly must keep replenishing its pipeline to cover R&D cost and to replace revenue lost to price controls, exclusivity expiry, and competitive displacement, and it notes that the growth of its revenue base raises the bar that future products must clear.

Business development risk. Lilly is an active acquirer and flags competition for targets, FTC and European regulatory scrutiny of pharmaceutical combinations, integration and retention failures, diligence that misses or under-sizes risks, and the resulting possibility of impairment or restructuring charges; deals in novel modalities carry added scientific uncertainty.

Government price controls and the U.S. pricing agreements. The filing treats the November 2025 agreements as a risk in their own right: definitive terms could be delayed or unfavorable, and Lilly may fail to capitalize on expanded U.S. obesity access if the revenue it generates does not offset the pricing concessions. Broader efforts to align U.S. prices with international benchmarks could pressure pricing, demand, and competitive position globally. More Lilly products are expected to be selected for IRA price-setting, accelerating revenue erosion before exclusivity ends, and the nine-year timeline for small-molecule drugs is described as reducing the attractiveness of small-molecule investment. Cash-pay obesity sales add exposure to pricing, economic conditions, and competing offerings.

Private-payer and channel power. Consolidated health plans, PBMs, and pharmacies use formularies, utilization management, and cost-sharing design to control spend. A named example: in July 2025 CVS Caremark stopped covering Zepbound as a preferred obesity medicine on some plans, which hurt access for patients on those plans. Continued expansion of the 340B program, including state laws purporting to require 340B sales to unlimited contract pharmacies, affects an increasing share of sales.

Intellectual property. Trulicity will lose significant patent and remaining data protection within the next few years. U.S. patents on major products are expected to be routinely challenged under Hatch-Waxman, the BPCIA, and inter partes review. The December 2025 EU legislative agreement-in-principle would make some IP incentives conditional and cut maximum data protection by one year, and U.S. "march-in rights" proposals and limits on patent families are also flagged.

Safety and efficacy after launch. Use in much larger populations can surface new safety or efficacy signals, leading to label changes, recalls, withdrawals, and product liability claims; concerns about same-class, compounded, or counterfeit products can be imputed to Lilly's medicines.

Manufacturing and supply. The capacity build cuts both ways: shortages cost revenue and invite competitors, while overestimating demand would strand capital spending, create supply imbalances, and could trigger significant contractual payment obligations. Regional and single-source dependencies, China-based suppliers in particular, add tariff and geopolitical exposure, and qualifying alternatives is slow and regulator-gated.

Third parties, AI, and IT. Lilly outsources parts of clinical trial management, testing, manufacturing, device assembly, and distribution, and has expanded relationships with contract manufacturers, consumer-access channel operators, and AI vendors. It warns that AI may empower new competitors, that its AI investments may not pay off, and that AI use compounds regulatory, cybersecurity, and data-privacy risk. Cyber incidents to date have not had a material impact on strategy, results, or financial condition.

International, currency, and tax. Large operations in Europe and Asia expose Lilly to single-payer cost containment (EU, Japan, China), tariffs and U.S.–China tensions, and geopolitical escalation. Lilly is a net receiver of most foreign currencies, so a strong dollar hurts results. Tax positions face routine examination and rising scrutiny of cross-border issues, plus global minimum tax regimes.

Litigation and regulation. Lilly faces a large volume of product, pricing, IP, and commercial-practice claims and is predominantly self-insured for liability losses on current and past products because the liability insurance market is very restrictive. Participation in novel programs such as the FDA Commissioner's National Priority Voucher pilot may attract legal, political, and reputational scrutiny.

Principal named legal matters (from Note 9 of the September 2026 Form 10-Q, accession 0000059478-26-000108):

  • Emgality patent litigation (Teva). After a 2022 jury verdict for Teva and a 2023 trial-court judgment for Lilly holding the asserted claims invalid, the Federal Circuit reversed the invalidity finding in April 2026 and remanded; Lilly recognized a charge in the first quarter of 2026, and in September 2026 the Federal Circuit denied Lilly's petition for rehearing en banc.
  • Verzenio Hatch-Waxman. Cipla filed an ANDA in April 2026; Lilly sued Cipla in Delaware in June 2026, and trial is scheduled for May 2028.
  • Tirzepatide Hatch-Waxman. In July 2026 multiple generic companies filed ANDAs seeking to market generic Mounjaro and/or Zepbound before some or all listed patents expire; Lilly filed patent infringement suits in Delaware in August 2026.
  • 340B and insulin pricing. Multiple state and provider suits over Lilly's contract-pharmacy and claims-data policies are pending in federal courts, alongside suits Lilly has brought challenging aspects of the program; insulin-pricing suits by consumers, states, municipalities, tribes, payers, and others are largely consolidated in a multidistrict litigation in New Jersey. Lilly also faces pricing investigations by the Department of Justice, the FTC, and state attorneys general.
  • Incretin product liability. Suits alleging injuries from Mounjaro, Trulicity, and Zepbound (also naming Novo Nordisk) are coordinated in two federal MDLs in the Eastern District of Pennsylvania, gastrointestinal injuries and NAION, with related state-court cases and two class action petitions each in Israel and Canada.
  • Health Choice Alliance. A Texas Medicaid Fraud Prevention Act qui tam; in August 2025 the relator purported to dismiss the first suit and filed a second adding the State of Texas and expanding the claims from three to fifteen products. Lilly is opposing the dismissal.
  • Actos. A third-party-payer class action in California in which Takeda is obliged to defend and indemnify Lilly; a defense summary-judgment motion filed in October 2025 remains pending.

Management's discussion and analysis, fiscal year 2025

From Item 7 of the FY2025 Form 10-K, accession 0000059478-26-000013.

Headline results

($ millions, except per-share)20252024Change
Revenue65,17945,043+45%
Net income20,64010,590+95%
Diluted EPS$22.95$11.71+96%

Revenue drivers. U.S. revenue rose 43 percent to $43,481 million and revenue outside the U.S. rose 48 percent to $21,698 million. Consolidated growth broke down into volume +50 percent, price −6 percent, foreign exchange +1 percent; in the U.S., volume was +53 percent and price −10 percent, both driven chiefly by Mounjaro and Zepbound.

Product ($ millions)20252024Change
Mounjaro22,96511,540+99%
Zepbound13,5424,926+175%
Verzenio5,7235,307+8%
Other products22,94923,270−1%
Revenue65,17945,043+45%

Mounjaro grew 53 percent in the U.S. on demand, partly offset by lower realized prices, while revenue outside the U.S. rose from $2.6 billion to $9.3 billion on volume. Zepbound grew 174 percent in the U.S. Verzenio grew 1 percent in the U.S. and 20 percent outside it.

Margins and expenses. Gross margin was $54,127 million, 83.0 percent of revenue, up 1.7 points, on favorable mix and improved production costs, partly offset by lower realized prices. R&D rose 21 percent to $13,337 million and marketing, selling, and administrative expense rose 29 percent to $11,094 million on launch support. Acquired IPR&D charges were $2,910 million (2024: $3,280 million), chiefly Scorpion Therapeutics' PI3Kα program STX-478 and SiteOne Therapeutics. The effective tax rate rose to 19.8 percent from 16.5 percent on jurisdictional earnings mix and 2025 U.S. tax law changes; both years were burdened by non-deductible acquired IPR&D.

Cash and capital. Operating cash flow rose to $16.8 billion from $8.8 billion, and cash and equivalents ended 2025 at $7.3 billion (2024: $3.3 billion), with a further $2.9 billion of investments. Capital expenditures were $7.8 billion versus $5.1 billion, and management expected meaningfully higher capex in the near term. Supply and contract-manufacturing agreements for medicines in development could require up to approximately $10 billion of payments if specified volumes are not purchased, over terms generally up to eight years. Total debt rose $8.9 billion to $42.5 billion, against $10.1 billion of unused committed bank facilities. Dividends paid were $6.00 per share (2024: $5.20), and the quarterly rate was raised to $1.73 from the first quarter of 2026, an indicated $6.92 a year. Lilly repurchased $4.1 billion of stock in 2025, leaving $10.9 billion under the $15.0 billion December 2024 authorization.

Pipeline at the time of the 10-K. Orforglipron had been submitted for obesity in the U.S., EU, and Japan, carrying an FDA Commissioner's National Priority Voucher, and for type 2 diabetes in the EU, with Phase 3 programs in cardiovascular outcomes, hypertension, sleep apnea, osteoarthritis pain, peripheral artery disease, and stress urinary incontinence. Insulin efsitora alfa was submitted in the U.S., EU, and Japan for type 2 diabetes. Tirzepatide's cardiovascular-outcomes indication in type 2 diabetes was submitted in the U.S., with Phase 3 programs in liver disease (MASLD), obesity morbidity and mortality, and type 1 diabetes. Retatrutide was in Phase 3 across obesity, osteoarthritis, sleep apnea, type 2 diabetes, cardiovascular and renal outcomes, chronic low back pain, and MASLD. Other Phase 3 programs included eloralintide, lepodisiran, muvalaplin, brenipatide (alcohol use disorder), remternetug, ixo-vec, olomorasib, sofetabart mipitecan, and imlunestrant in adjuvant breast cancer.

Other matters. The One Big Beautiful Bill Act, enacted in July 2025, made permanent several Tax Cuts and Jobs Act provisions, including immediate deductibility of U.S. R&D expense and 100 percent bonus depreciation.


Current quarter, three and nine months ended September 30, 2026

From the Form 10-Q, accession 0000059478-26-000108, and the third-quarter earnings release furnished on Form 8-K, accession 0000059478-26-000104.

Results

($ millions, except per-share)Q3 2026Q3 2025Change9M 20269M 2025Change
Revenue24,39717,601+39%67,17045,887+46%
Net income6,4515,583+16%20,94214,002+50%
Diluted EPS$7.22$6.21+16%$23.42$15.56+51%

Revenue grew on volume, partly offset by lower realized prices. Net income rose mainly on higher gross margin, partly offset by higher acquired IPR&D charges, R&D, and marketing, selling, and administrative expense. U.S. revenue rose 34 percent to $15,136 million and revenue outside the U.S. rose 47 percent to $9,261 million. The quarter's consolidated revenue change broke down into volume +53 percent and price −15 percent, with no foreign exchange effect:

  • U.S.: volume +41 percent, led by Zepbound and Mounjaro; price −7 percent, driven mainly by Zepbound and partly offset by favorable adjustments to rebate and discount estimates, mostly on Mounjaro. Changes in estimates for U.S. rebate, discount, and return liabilities on products shipped in earlier periods equalled 2 percent of U.S. revenue in both the quarter and the nine months, against less than 1 percent a year earlier.
  • Outside the U.S.: volume +76 percent, led by Mounjaro; price −29 percent, driven mainly by Mounjaro's inclusion on China's National Reimbursement Drug List. By region, Europe contributed $4,459 million (Q3 2025: $3,498 million), China $947 million ($560 million), Japan $648 million ($555 million), and the rest of the world $3,206 million ($1,688 million).

The earnings release says Q3 revenue included approximately $900 million of benefits, mainly $410 million of Jardiance sales-based milestones from Boehringer Ingelheim (Q3 2025: $200 million) and the favorable rebate-estimate adjustments. Jardiance milestones totalled $910 million over the nine months, and no further milestones remain to be earned under the collaboration. The prior-year quarter included $180 million from divesting Cialis rights in select markets outside the U.S.

Product, Q3 ($ millions)20262025Change
Mounjaro10,7236,515+65%
Zepbound5,3523,588+49%
Jardiance1,578959+65%
Verzenio1,5111,470+3%
Trulicity9041,052−14%
Taltz856902−5%
Other3,4743,115+12%
Revenue24,39717,601+39%

Mounjaro grew 41 percent in the U.S. to $5.0 billion and 93 percent outside it to $5.7 billion, so it now earns more abroad than at home. U.S. Zepbound revenue rose 48 percent to $5.3 billion. Among newer launches, the release lists Jaypirca at $228 million, Ebglyss $202 million, Kisunla $193 million, Foundayo (orforglipron) $184 million in its second quarter on the market (nine months: $281 million), Omvoh $114 million, and Inluriyo $73 million; it says the company's key products in immunology, oncology, and neuroscience together doubled from a year earlier. Mounjaro, Zepbound, and Foundayo together accounted for 66 percent of nine-month revenue, up from 56 percent for Mounjaro and Zepbound in full-year 2025.

Margins and charges. Gross margin was $20,464 million, 83.9 percent of revenue, up 1.0 point, on lower production costs and favorable mix, partly offset by lower prices. R&D rose 23 percent to $4,247 million (17 percent of revenue) and marketing, selling, and administrative expense rose 14 percent to $3,125 million. Acquired IPR&D charges were $4,181 million against $656 million a year earlier, chiefly from the AtaiBeckley ($2,610 million) and Curevo ($954 million) asset acquisitions. Asset impairment, restructuring, and other special charges were $303 million, a partial impairment of an intangible asset tied to a molecule in development. Net interest expense rose to $316 million from $114 million. The effective tax rate was 23.3 percent against 22.8 percent, pushed up by non-deductible acquired IPR&D. Acquired IPR&D cost $4.57 of EPS in the quarter against $0.71 a year earlier. Non-GAAP EPS was $7.48, up 7 percent; the non-GAAP measure adds back intangible amortization ($0.11) and the special charges ($0.18) and removes equity-investment gains ($0.04), but does not exclude acquired IPR&D.

Business development in 2026. The year's deals show up on the balance sheet: goodwill rose to $9,874 million from $5,898 million and other intangibles to $18,084 million from $6,521 million. The significant deals that closed as business combinations were:

  • Ventyx Biosciences, closed March 4, 2026; oral therapies for inflammatory diseases (lead asset VTX3232); consideration fair value $1,178 million.
  • Centessa Pharmaceuticals, closed June 24, 2026; orexin receptor 2 agonists for sleep-wake disorders (ORX750); consideration fair value $6,593 million, including up to $1,542 million of contingent consideration at its maximum.
  • Kelonia Therapeutics, closed June 25, 2026; in vivo CAR-T therapies (KLN-1010); consideration fair value $4,897 million, with contingent consideration of up to $3,750 million at its maximum.

The significant asset acquisitions, expensed as acquired IPR&D, were:

  • Orna Therapeutics, May 2026; in vivo CAR-T for B-cell autoimmune disease; $1,233 million.
  • Ajax Therapeutics, June 2026; oral JAK2 inhibitor for myelofibrosis and polycythemia vera; $909 million.
  • Curevo, July 2026; amezosvatein, a Phase 2 shingles vaccine; $954 million. The second-quarter earnings release says Lilly completed three acquisitions to build an infectious disease portfolio after the quarter ended, without naming them; Curevo is the only infectious-disease acquisition Lilly's filings identify.
  • AtaiBeckley, September 2026; BPL-003, a Phase 2 synthetic 5-MeO-DMT for treatment-resistant depression; $2,610 million.

Lilly paid $18.2 billion for business development in the nine months. Contingent consideration liabilities stood at $2,888 million across current and noncurrent balances, up from $251 million at year-end, mainly because of Kelonia.

Financial condition. Nine-month operating cash flow was $27.4 billion (9M 2025: $13.6 billion), against $8.4 billion of property and equipment purchases (9M 2025: $5.3 billion). Investing outflows of $27.6 billion, including the business development payments, and financing outflows of $2.3 billion, dividends of $4.6 billion ($5.19 per share) and $4.3 billion of buybacks, net of new borrowing, took cash and equivalents down to $4.9 billion from $7.3 billion at year-end. Investments rose to $4.1 billion. Total debt was $49.5 billion, up $7.0 billion from year-end. In May 2026 Lilly issued $9.0 billion of notes, with maturities from 2028 to 2066, fixed coupons of 4.150 to 5.700 percent, and $1.3 billion of floating-rate notes at SOFR plus 0.350 and 0.460 percent. Net proceeds of about $8.94 billion went to general corporate purposes, including repaying commercial paper and funding part of the Centessa and Kelonia consideration. In August 2026 Lilly renewed its $6.0 billion 364-day credit facility and refinanced its $4.0 billion multi-year facility, extending it to August 2031; neither was drawn, leaving $10.1 billion of unused committed facilities. Third-quarter buybacks were $374 million at an average of about $1,168 per share, and $6.6 billion remains under the $15.0 billion authorization. Inventories rose to $18.2 billion from $13.7 billion, and net property and equipment to $32.2 billion from $24.7 billion. Unfunded venture capital commitments were about $862 million.

Pipeline and regulatory changes since the 10-K. The FDA approved orforglipron for obesity, launched in the U.S. as Foundayo in the second quarter. The CHMP recommended it in the EU for obesity and type 2 diabetes, and it has been submitted for type 2 diabetes in the U.S. and Japan. The FDA also approved insulin efsitora alfa as Onswik, a once-weekly basal insulin for type 2 diabetes (with a positive CHMP opinion in the EU), and tirzepatide to reduce cardiovascular risk in type 2 diabetes. Phase 3 trials of retatrutide met their primary endpoints in obesity and in type 2 diabetes. The third-quarter release adds a positive head-to-head Phase 3 result against Ozempic 2 mg in type 2 diabetes, and positive Phase 2 results for EloraTZP (eloralintide plus tirzepatide) in obesity with type 2 diabetes, with Phase 3 trials to start in the fourth quarter of 2026. New Phase 3 starts since the 10-K include:

  • baricitinib in type 1 diabetes;
  • eloralintide as an incretin add-on for obesity, and in sleep apnea and osteoarthritis pain;
  • brenipatide in major depressive disorder;
  • sofetabart mipitecan in platinum-sensitive ovarian cancer (it also holds Breakthrough Therapy designation in platinum-resistant disease);
  • tersolisib in PIK3CA-mutant advanced breast cancer.

Other FDA approvals cited in the release include Inluriyo with Verzenio in ESR1-mutated advanced breast cancer, Jaypirca in previously untreated CLL/SLL, and Olumiant for severe alopecia areata in patients 12 and older.

Access. Lilly has entered into its voluntary agreements with the U.S. government. Under the Medicare GLP-1 Bridge program, Medicare beneficiaries gained access to discounted Lilly obesity medicines from July 1, 2026 through December 31, 2027, and state Medicaid programs can separately expand access. Lilly continues to engage with CMS on long-term Medicare coverage and says continued uptake from the expanded access is unknown.

Guidance (earnings release). Lilly raised full-year 2026 guidance as follows:

MeasurePriorUpdated
Revenue$85–$87 billion$91–$92 billion
Performance margin (gross margin less R&D and SG&A, over revenue)49.0–50.5%52.0–52.5%
Tax rate18–19%19–20%
Non-GAAP EPS$35.50–$36.50$35.00–$36.00

The EPS change nets a $4.07 midpoint increase from underlying performance against $4.57 of third-quarter acquired IPR&D charges. The company notes that the first three quarters benefited from sales-based milestones and rebate-estimate adjustments. Guidance excludes acquired IPR&D incurred after September 30, 2026 and assumes about 894 million shares and exchange rates of 1.13 (euro), 157 (yen), and 6.7 (yuan).

What management says will drive the near term. Management names three swing factors: the timing of further orforglipron approvals; demand and uptake in new incretin channels and markets, including U.S. Medicare for Zepbound and Foundayo; and incretin volume swings from channel dynamics, which can affect any single period disproportionately. Longer term, management ties durability to defending its competitive position as the obesity and diabetes market evolves.


Subsequent events

From Note 4, Note 6, and Item 2 of the Form 10-Q, accession 0000059478-26-000108, and the earnings release, accession 0000059478-26-000104. The company evaluated subsequent events through the filing of the quarterly report on October 29, 2026.

  • Merida Biosciences acquisition (October 2026). Lilly acquired Merida Biosciences, Inc. for up to $2.9 billion in aggregate, comprising an upfront payment plus potential payments tied to clinical and regulatory milestones; the release describes Merida as developing treatments for serious autoimmune and allergic diseases. The upfront amount is not disclosed separately. Because Lilly's access to information before closing was limited, the fair values of the assets acquired and liabilities assumed, and the accounting treatment, had not yet been determined.
  • IRS examination (October 2026). The IRS began examining Lilly's 2022–2024 tax years; the 2019–2021 examination remains open, and Lilly is pursuing competent-authority relief through the Mutual Agreement Procedure for 2016–2018 intercompany pricing. Resolution is expected to take longer than 12 months.
  • Fourth-quarter dividend (October 2026). Lilly declared a dividend of $1.73 per share, approximately $1.5 billion, payable December 10, 2026 to shareholders of record on November 13, 2026.

AI synthesis of events in 16 filings

Filings that contain financial statements

Each earnings release below is an Exhibit 99.1 to a Form 8-K (Item 2.02) and carries a reported income statement and a GAAP-to-non-GAAP reconciliation. None of them carries a balance sheet or cash flow statement; those are in the Form 10-Q and Form 10-K.

  • Form 8-K, October 29, 2026, accession 0000059478-26-000104: income statement and reconciliation for the three and nine months ended September 30, 2026.
  • Form 8-K, August 5, 2026, accession 0000059478-26-000077: income statement and reconciliation for the three and six months ended June 30, 2026.
  • Form 8-K, April 30, 2026, accession 0000059478-26-000043: income statement and reconciliation for the three months ended March 31, 2026.
  • Form 8-K, February 4, 2026, accession 0000059478-26-000008: income statement and reconciliation for the fourth quarter and full year ended December 31, 2025.

Earnings and guidance

Third quarter 2026 (8-K filed October 29, 2026, accession 0000059478-26-000104). Revenue rose 39% to $24.4 billion, driven by Mounjaro ($10.7 billion) and Zepbound ($5.4 billion). Reported EPS was $7.22 (up 16%) and non-GAAP EPS $7.48 (up 7%). Both include $4.57 per share of acquired IPR&D charges, against $0.71 a year earlier. The release says Q3 revenue included about $900 million of benefits, mainly $410 million of Jardiance milestones (it says no further milestones remain) and favorable rebate and discount estimate adjustments. Realized prices fell 15% while volume rose 53%.

Full-year 2026 guidance was raised again:

  • Revenue: $91.0 to $92.0 billion, from $85 to $87 billion.
  • Performance margin: 52.0% to 52.5%, from 49.0% to 50.5%.
  • Tax rate: 19% to 20%, from 18% to 19%.
  • Non-GAAP EPS: $35.00 to $36.00, from $35.50 to $36.50. Underlying EPS was raised by $4.07 at the midpoint, more than offset by $4.57 of Q3 acquired IPR&D charges. Guidance excludes IPR&D incurred after September 30, 2026.

Second quarter 2026 (8-K filed August 5, 2026, accession 0000059478-26-000077). Revenue rose 48% to $23.0 billion. Reported EPS was $7.94 and non-GAAP EPS $8.38, including $3.03 of acquired IPR&D charges. Full-year revenue guidance rose to $85 to $87 billion (from $82 to $85 billion) and EPS guidance moved to $35.50 to $36.50. The release says the retatrutide Phase 3 data package is complete and plans a U.S. Biologics License Application submission in the first quarter of 2027.

First quarter 2026 (8-K filed April 30, 2026, accession 0000059478-26-000043). Revenue rose 56% to $19.8 billion. Reported EPS was $8.26 and non-GAAP EPS $8.55. Guidance rose to revenue of $82 to $85 billion (from $80 to $83 billion) and non-GAAP EPS of $35.50 to $37.00 (from $33.50 to $35.00). The U.S. FDA approved Foundayo (orforglipron) for obesity. The company announced an Investment Community Meeting for December 7, 2026.

Fourth quarter 2025 and 2026 guidance (8-K filed February 4, 2026, accession 0000059478-26-000008). Fourth-quarter revenue rose 43% to $19.3 billion; full-year 2025 revenue was $65.2 billion. Initial 2026 guidance was revenue of $80 to $83 billion, performance margin of 46.0% to 47.5%, a tax rate of 18% to 19%, and non-GAAP EPS of $33.50 to $35.00. The release also notes an agreement with the U.S. government to expand access to obesity medicines.

Earlier in the cycle. An 8-K dated January 14, 2025 (accession 0000059478-25-000005) furnished preliminary 2024 revenue of about $45.0 billion, with fourth-quarter 2024 revenue about $400 million below the low end of prior guidance, and first 2025 revenue guidance of $58 to $61 billion. Earnings 8-Ks were also filed February 6, 2025 (0000059478-25-000037), May 1, 2025 (0000059478-25-000129), August 7, 2025 (0000059478-25-000202) and October 30, 2025 (0000059478-25-000251).

Acquisitions and business development

The company's 8-Ks and the Form 10-Q (accession 0000059478-26-000108) show these transactions, with status as stated in the filings:

  • Centessa Pharmaceuticals plc: completed. The April 30 release described an agreement to acquire. A May 20, 2026 debt 8-K (below) said the deal was still unconsummated, with a special mandatory redemption if it did not close by an outside date of March 31, 2027 or later. The Form 10-Q gives an acquisition date of June 24, 2026, and the August 5 release lists it as completed. Fair value of consideration was $6.6 billion, of which $6.1 billion is acquired IPR&D (ORX750, an orexin receptor 2 agonist); cash paid net of cash acquired was $6.0 billion, with up to $1.5 billion of contingent payments.
  • Kelonia Therapeutics: completed June 25, 2026 (Form 10-Q). In vivo CAR-T therapies; consideration fair value $4.9 billion, cash paid net $3.1 billion, contingent payments up to $3.75 billion.
  • Ventyx Biosciences: completed March 4, 2026 (Form 10-Q). Consideration fair value $1.2 billion, cash paid net $1.1 billion.
  • Orna Therapeutics (May 2026) and Ajax Therapeutics (June 2026): completed, per the August 5 release and Form 10-Q, with acquired IPR&D charges of $1.2 billion and $0.9 billion.
  • Curevo Inc.: completed July 2026, acquired IPR&D charge $954 million (Form 10-Q). The August 5 release says three acquisitions to build an infectious disease portfolio were completed after quarter end.
  • AtaiBeckley Inc.: agreement announced by August 5, 2026; completed September 2026, acquired IPR&D charge $2.6 billion (October 29 release and Form 10-Q).
  • Merida Biosciences: acquired October 2026, for up to $2.9 billion including milestones (Form 10-Q subsequent event). The October 29 release says the acquisition was completed after quarter end, although its public-announcement list still shows "to acquire".

Acquired IPR&D charges were $4.2 billion in Q3 2026 and $7.5 billion for the nine months, against $0.7 billion and $2.4 billion a year earlier.

Capital actions

  • May 2026 notes offering (8-K dated May 20, 2026, accession 0001193125-26-232707). Lilly completed an offering of $9.0 billion of notes: $750 million of floating rate notes due 2028, $500 million floating rate due 2029, and fixed-rate notes of $750 million at 4.150% due 2029, $1.5 billion at 4.375% due 2031, $1.25 billion at 4.650% due 2033, $1.5 billion at 4.850% due 2036, $1.75 billion at 5.600% due 2056 and $1.0 billion at 5.700% due 2066. The 2029 floating rate notes and the 2029, 2031, 2033 and 2036 fixed-rate notes are subject to special mandatory redemption at 101% if the Centessa acquisition does not close by the outside date; that acquisition has since closed. The Form 10-Q says proceeds went to repay commercial paper and fund part of the Centessa and Kelonia cash consideration.
  • Credit facilities (Form 10-Q). In August 2026 the $6.0 billion 364-day facility was renewed and the $4.0 billion multi-year facility was refinanced to expire in August 2031; neither was drawn at September 30, 2026. Long-term debt, including current portion, was $49.5 billion at September 30, 2026, against $42.5 billion at December 31, 2025.
  • Earlier notes offerings. Underwriting agreements for $6.5 billion of notes in February 2025 (8-K accession 0001193125-25-025057) and a $6.75 billion offering in August 2025 (accession 0001193125-25-184093), the latter including $750 million of floating rate notes due 2028.
  • Share repurchases (Form 10-Q). $4.3 billion repurchased in the first nine months of 2026, of which $374 million in Q3, leaving $6.6 billion under the $15.0 billion program authorized in December 2024.
  • Dividend. The October 29 release shows dividends paid of $1.73 per share in Q3 2026, against $1.50 in Q3 2025.

Governance

  • Annual meeting, May 4, 2026 (8-K accession 0000059478-26-000048). All four director nominees were elected. Proposals to eliminate the classified board and supermajority voting provisions did not receive the required 80% of outstanding shares. A shareholder proposal for an independent board chair was not approved.
  • Board appointment (8-K filed November 21, 2025, accession 0000059478-25-000271). Carolyn R. Bertozzi, Ph.D. was elected a director effective December 8, 2025.
  • Annual meeting, May 5, 2025 (accession 0000059478-25-000138). Routine voting results.
  • Executive change (October 29, 2026 release). Patrik Jonsson will retire after 36 years; Ilya Yuffa was named president, Lilly Global Markets.

Regulatory and pipeline items named in the earnings releases

Through the October 29, 2026 release: U.S. FDA approvals of Mounjaro for cardiovascular risk reduction in adults with type 2 diabetes, Onswik (once-weekly basal insulin), Inluriyo with Verzenio, and an expanded Jaypirca indication. Positive Phase 3 head-to-head results for retatrutide versus Ozempic 2 mg, and Phase 3 trials of EloraTZP to start in Q4 2026.

Not in these filings

No restructuring, going-concern or covenant matters appear in the 8-Ks reviewed.

Financials

Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. A figure with no link was either derived by AI, such as a margin, free cash flow or a trailing-twelve-month total, or taken from a filing that does not tag its numbers, such as an earnings release.

About this file

TickerLLY
CIK0000059478
CompanyEli Lilly and Company
Business typepharmaceutical manufacturer
Schema templatepharmaceutical manufacturer
Reporting currencyUSD
Converted to USDno
Unitsactual dollars (not millions)

LLY annual income statement, balance sheet and cash flow

Taken from the SEC filings and normalized to actual dollars.

FY2025FY2024FY2023
Period start2025-01-012024-01-012023-01-01
Period end2025-12-312024-12-312023-12-31
Period typefiscal yearfiscal yearfiscal year
Source accession10-K10-K10-K
Income statement
Revenue65,179,000,00045,043,000,00034,124,000,000
Cost of sales11,052,000,0008,418,000,0007,082,000,000
Gross profit54,127,000,00036,625,000,00027,042,000,000
Gross margin %83.0%81.3%79.2%
Research and development13,337,000,00010,991,000,0009,313,000,000
Marketing selling and administrative11,094,000,0008,594,000,0007,404,000,000
Acquired in process research and development2,910,000,0003,280,000,0003,800,000,000
Asset impairment restructuring and other special charges484,000,000861,000,00068,000,000
Other net expense income571,000,000219,000,000-97,000,000
Total costs expenses and other39,448,000,00032,363,000,00027,570,000,000
Operating income derived26,302,000,00012,899,000,0006,457,000,000
Income before income taxes25,731,000,00012,680,000,0006,554,000,000
Income taxes5,091,000,0002,090,000,0001,314,000,000
Effective tax rate %19.8%16.5%20.0%
Net income20,640,000,00010,590,000,0005,240,000,000
Net margin %31.7%23.5%15.4%
EPS basic23.0011.765.82
EPS diluted22.9511.715.80
Weighted average shares basic897,300,000900,600,000900,200,000
Weighted average shares diluted899,300,000904,100,000903,300,000
Dividends declared per share6.235.404.69
Revenue by geography
US43,481,000,00030,375,000,00021,791,000,000
Outside US21,698,000,00014,668,000,00012,333,000,000
Total65,179,000,00045,043,000,00034,124,000,000
Revenue by product
Mounjaro
US13,651,000,0008,950,000,0004,834,000,000
Outside US9,315,000,0002,590,000,000329,000,000
Total22,965,000,00011,540,000,0005,163,000,000
Zepbound
US13,484,000,0004,926,000,000176,000,000
Outside US58,000,00000
Total13,542,000,0004,926,000,000176,000,000
Verzenio
US3,464,000,0003,421,000,0002,509,000,000
Outside US2,259,000,0001,886,000,0001,354,000,000
Total5,723,000,0005,307,000,0003,863,000,000
Trulicity
US2,914,000,0003,694,000,0005,433,000,000
Outside US1,362,000,0001,560,000,0001,699,000,000
Total4,276,000,0005,254,000,0007,132,000,000
Jardiance
US1,582,000,0001,598,000,0001,600,000,000
Outside US1,849,000,0001,743,000,0001,144,000,000
Total3,431,000,0003,341,000,0002,744,000,000
Taltz
US2,333,000,0002,152,000,0001,832,000,000
Outside US1,230,000,0001,108,000,000928,000,000
Total3,563,000,0003,260,000,0002,760,000,000
Revenue by therapeutic area
Cardiometabolic health
US33,864,000,00021,850,000,00014,781,000,000
Outside US14,357,000,0007,671,000,0004,887,000,000
Total48,221,000,00029,521,000,00019,668,000,000
Oncology
US5,352,000,0005,036,000,0003,797,000,000
Outside US4,024,000,0003,717,000,0002,861,000,000
Total9,376,000,0008,753,000,0006,658,000,000
Immunology
US2,964,000,0002,458,000,0002,058,000,000
Outside US2,283,000,0001,935,000,0001,740,000,000
Total5,247,000,0004,393,000,0003,798,000,000
Neuroscience
US997,000,000780,000,000696,000,000
Outside US394,000,000694,000,0002,183,000,000
Total1,391,000,0001,474,000,0002,879,000,000
Other
US304,000,000251,000,000459,000,000
Outside US639,000,000652,000,000663,000,000
Total943,000,000903,000,0001,122,000,000
Balance sheet
Cash and cash equivalents7,268,000,0003,268,000,000
Accounts receivable17,760,000,00011,006,000,000
Other receivables2,395,000,0002,270,000,000
Inventories13,744,000,0007,589,000,000
Prepaid expenses14,315,000,0008,341,000,000
Other current assets147,000,000266,000,000
Total current assets55,629,000,00032,740,000,000
Investments noncurrent2,802,000,0003,216,000,000
Goodwill5,898,000,0005,770,000,000
Other intangibles net6,521,000,0006,166,000,000
Deferred tax assets9,959,000,0008,001,000,000
Property and equipment net24,675,000,00017,102,000,000
Other noncurrent assets6,992,000,0005,720,000,000
Total assets112,476,000,00078,715,000,000
Short term borrowings and current maturities of long term debt1,635,000,0005,117,000,000
Accounts payable5,379,000,0003,229,000,000
Employee compensation2,375,000,0002,094,000,000
Sales rebates and discounts17,382,000,00011,539,000,000
Other current liabilities8,457,000,0006,397,000,000
Total current liabilities35,228,000,00028,376,000,000
Long term debt40,868,000,00028,527,000,000
Long term income taxes payable5,875,000,0004,061,000,000
Other noncurrent liabilities3,970,000,0003,479,000,000
Total noncurrent liabilities50,713,000,00036,067,000,000
Total liabilities85,941,000,00064,443,000,000
Common stock590,000,000592,000,000
Additional paid in capital7,346,000,0007,439,000,000
Retained earnings24,470,000,00013,545,000,000
Employee benefit trust-3,013,000,000-3,013,000,000
Accumulated other comprehensive loss-2,880,000,000-4,322,000,000
Other equity22,000,00031,000,000
Total equity26,535,000,00014,272,000,000
Total liabilities and equity112,476,000,00078,715,000,000
Total debt42,503,000,00033,644,000,000
Net debt35,235,000,00030,376,000,000
Issued shares at period end944,800,000947,900,000
Cash flow
Net income20,640,000,00010,590,000,0005,240,000,000
Depreciation and amortization1,997,000,0001,767,000,0001,527,000,000
Change in deferred income taxes-1,707,000,000-2,683,000,000-2,341,000,000
Stock based compensation626,000,000646,000,000629,000,000
Gains on sale of product rights-180,000,000-224,000,000-1,879,000,000
Acquired in process research and development noncash2,910,000,0003,280,000,0003,800,000,000
Other operating activities net620,000,000826,000,000319,000,000
Change in receivables-7,000,000,000-2,155,000,000-2,451,000,000
Change in inventories-4,671,000,000-2,507,000,000-1,425,000,000
Change in prepaid expenses and other assets-6,609,000,000-3,331,000,000-3,453,000,000
Change in accounts payable and other liabilities10,187,000,0002,609,000,0004,274,000,000
Operating cash flow16,813,000,0008,818,000,0004,240,000,000
Capital expenditures-7,841,000,000-5,058,000,000-3,448,000,000
Proceeds from sales of and distributions from noncurrent investments964,000,000374,000,000508,000,000
Purchases of noncurrent investments-645,000,000-677,000,000-731,000,000
Proceeds from sale of product rights218,000,000601,000,0001,604,000,000
Purchases of in process research and development-3,008,000,000-3,346,000,000-3,944,000,000
Cash paid for acquisitions net of cash acquired-661,000,000-948,000,000-1,044,000,000
Other investing activities net1,000,000-248,000,000-98,000,000
Investing cash flow-10,972,000,000-9,302,000,000-7,153,000,000
Dividends paid-5,384,000,000-4,680,000,000-4,069,000,000
Net change in short term borrowings-4,338,000,000-1,852,000,0004,691,000,000
Proceeds from issuance of long term debt13,167,000,00011,417,000,0003,959,000,000
Repayments of long term debt-778,000,000-664,000,0000
Share repurchases-4,108,000,000-2,500,000,000-750,000,000
Other financing activities net-772,000,000-491,000,000-335,000,000
Financing cash flow-2,213,000,0001,230,000,0003,496,000,000
Effect of exchange rate changes on cash372,000,000-297,000,000169,000,000
Net change in cash4,000,000,000449,000,000752,000,000
Cash at beginning of year3,268,000,0002,819,000,0002,067,000,000
Cash at end of year7,268,000,0003,268,000,0002,819,000,000
Free cash flow8,972,000,0003,760,000,000792,000,000

LLY quarterly income statement, balance sheet and cash flow

Taken from the SEC filings and normalized to actual dollars.

Q3 2026Q3 2025
Fiscal periodQ3 2026Q3 2025
Period start2026-07-012025-07-01
Period end2026-09-302025-09-30
Period typethree monthsthree months
Source accession10-Q10-Q
Income statement
Revenue24,397,000,00017,601,000,000
Cost of sales3,933,000,0003,008,000,000
Research and development4,247,000,0003,466,000,000
Marketing selling and administrative3,125,000,0002,741,000,000
Acquired in process research and development4,181,000,000656,000,000
Asset impairment restructuring and other special charges303,000,000365,000,000
Other net expense income202,000,000132,000,000
Total costs expenses and other15,991,000,00010,368,000,000
Income before income taxes8,406,000,0007,233,000,000
Income taxes1,955,000,0001,650,000,000
Net income6,451,000,0005,583,000,000
EPS basic7.236.22
EPS diluted7.226.21
Weighted average shares basic891,900,000896,900,000
Weighted average shares diluted893,400,000898,800,000
Revenue by product
Mounjaro
US4,998,000,0003,550,000,000
Outside US5,725,000,0002,965,000,000
Total10,723,000,0006,515,000,000
Zepbound
US5,267,000,0003,568,000,000
Outside US86,000,00020,000,000
Total5,352,000,0003,588,000,000
Jardiance
US781,000,000424,000,000
Outside US796,000,000535,000,000
Total1,578,000,000959,000,000
Trulicity
US601,000,000707,000,000
Outside US302,000,000345,000,000
Total904,000,0001,052,000,000
Verzenio
US897,000,000880,000,000
Outside US614,000,000590,000,000
Total1,511,000,0001,470,000,000
Taltz
US539,000,000583,000,000
Outside US316,000,000318,000,000
Total856,000,000902,000,000
Revenue by therapeutic area
Cardiometabolic health
US12,376,000,0008,867,000,000
Outside US7,388,000,0004,311,000,000
Total19,764,000,00013,178,000,000
Oncology
US1,518,000,0001,375,000,000
Outside US1,082,000,0001,033,000,000
Total2,600,000,0002,408,000,000
Immunology
US801,000,000773,000,000
Outside US634,000,000589,000,000
Total1,435,000,0001,362,000,000
Neuroscience
US384,000,000240,000,000
Outside US59,000,00076,000,000
Total444,000,000316,000,000
Other
US57,000,00045,000,000
Outside US97,000,000292,000,000
Total154,000,000337,000,000
Revenue by geography
US15,136,000,00011,300,000,000
Outside US9,261,000,0006,301,000,000
Total24,397,000,00017,601,000,000
Gross profit20,464,000,00014,593,000,000
Gross margin %83.9%82.9%
Operating income derived8,608,000,0007,365,000,000
Effective tax rate %23.3%22.8%
Net margin %26.4%31.7%
Balance sheet
Cash and cash equivalents4,885,000,000
Accounts receivable22,089,000,000
Other receivables3,142,000,000
Inventories18,194,000,000
Prepaid expenses16,862,000,000
Other current assets91,000,000
Total current assets65,263,000,000
Investments noncurrent4,013,000,000
Goodwill9,874,000,000
Other intangibles net18,084,000,000
Deferred tax assets10,955,000,000
Property and equipment net32,188,000,000
Other noncurrent assets7,695,000,000
Total assets148,072,000,000
Short term borrowings and current maturities of long term debt2,517,000,000
Accounts payable5,793,000,000
Employee compensation2,292,000,000
Sales rebates and discounts24,170,000,000
Other current liabilities12,224,000,000
Total current liabilities46,996,000,000
Long term debt46,986,000,000
Long term income taxes payable6,070,000,000
Other noncurrent liabilities7,749,000,000
Total noncurrent liabilities60,805,000,000
Common stock588,000,000
Additional paid in capital7,309,000,000
Retained earnings37,969,000,000
Employee benefit trust-3,013,000,000
Accumulated other comprehensive loss-2,629,000,000
Other equity47,000,000
Total equity40,271,000,000
Total liabilities and equity148,072,000,000
Issued shares at period end941,200,000
Shares outstanding on cover940,745,031
Total liabilities107,801,000,000
Total debt49,503,000,000
Net debt44,618,000,000
Shares outstanding cover date2026-10-26
Cash flow
Net income6,451,000,0005,582,000,000
Depreciation and amortization545,000,000470,000,000
Change in deferred income taxes-665,000,000501,000,000
Stock based compensation200,000,000151,000,000
Acquired in process research and development noncash4,181,000,000655,000,000
Other changes in operating assets and liabilities435,000,0001,208,000,000
Other operating activities net250,000,000268,000,000
Operating cash flow11,397,000,0008,835,000,000
Capital expenditures-3,178,000,000-2,087,000,000
Purchases of noncurrent investments-258,000,000-150,000,000
Purchases of in process research and development-4,062,000,000-720,000,000
Cash paid for acquisitions net of cash acquired-887,000,000-549,000,000
Other investing activities net86,000,000524,000,000
Investing cash flow-8,299,000,000-2,982,000,000
Dividends paid-1,541,000,000-1,346,000,000
Net change in short term borrowings-5,284,000,000-4,092,000,000
Proceeds from issuance of long term debt06,706,000,000
Repayments of long term debt00
Share repurchases-377,000,000-708,000,000
Other financing activities net-17,000,000-29,000,000
Financing cash flow-7,219,000,000531,000,000
Effect of exchange rate changes on cash56,000,00032,000,000
Net change in cash-4,065,000,0006,416,000,000
Cash at beginning of period8,950,000,0003,376,000,000
Cash at end of period4,885,000,0009,792,000,000
Free cash flow8,219,000,0006,748,000,000

LLY year-to-date income statement and cash flow

Taken from the SEC filings and normalized to actual dollars.

Nine months ended September 30, 2026Nine months ended September 30, 2025
Period start2026-01-012025-01-01
Period end2026-09-302025-09-30
Period typenine monthsnine months
Source accession10-Q10-Q
Income statement
Revenue67,170,000,00045,887,000,000
Cost of sales10,778,000,0007,680,000,000
Research and development11,576,000,0009,536,000,000
Marketing selling and administrative9,489,000,0007,963,000,000
Acquired in process research and development7,541,000,0002,381,000,000
Asset impairment restructuring and other special charges1,285,000,000400,000,000
Other net expense income-2,000,000462,000,000
Total costs expenses and other40,667,000,00028,422,000,000
Income before income taxes26,503,000,00017,465,000,000
Income taxes5,561,000,0003,463,000,000
Net income20,942,000,00014,002,000,000
EPS basic23.4515.60
EPS diluted23.4215.56
Weighted average shares basic892,900,000897,800,000
Weighted average shares diluted894,400,000899,700,000
Revenue by product
Mounjaro
US14,022,000,0009,508,000,000
Outside US15,306,000,0006,048,000,000
Total29,328,000,00015,556,000,000
Zepbound
US14,273,000,0009,254,000,000
Outside US167,000,00028,000,000
Total14,440,000,0009,281,000,000
Jardiance
US1,909,000,0001,116,000,000
Outside US2,014,000,0001,547,000,000
Total3,924,000,0002,663,000,000
Trulicity
US2,109,000,0002,221,000,000
Outside US932,000,0001,018,000,000
Total3,042,000,0003,239,000,000
Verzenio
US2,448,000,0002,467,000,000
Outside US1,838,000,0001,651,000,000
Total4,286,000,0004,118,000,000
Taltz
US1,495,000,0001,609,000,000
Outside US949,000,000902,000,000
Total2,444,000,0002,511,000,000
Revenue by therapeutic area
Cardiometabolic health
US34,041,000,00023,807,000,000
Outside US19,836,000,0009,922,000,000
Total53,877,000,00033,729,000,000
Oncology
US4,218,000,0003,840,000,000
Outside US3,219,000,0002,929,000,000
Total7,437,000,0006,769,000,000
Immunology
US2,211,000,0002,052,000,000
Outside US1,844,000,0001,654,000,000
Total4,055,000,0003,706,000,000
Neuroscience
US1,002,000,000677,000,000
Outside US253,000,000255,000,000
Total1,254,000,000932,000,000
Other
US197,000,000227,000,000
Outside US349,000,000525,000,000
Total546,000,000752,000,000
Revenue by geography
US41,668,000,00030,604,000,000
Outside US25,502,000,00015,283,000,000
Total67,170,000,00045,887,000,000
Gross profit56,392,000,00038,207,000,000
Gross margin %84.0%83.3%
Operating income derived26,501,000,00017,927,000,000
Effective tax rate %21.0%19.8%
Net margin %31.2%30.5%
Dividends declared per share3.463.00
Cash flow
Net income20,942,000,00014,002,000,000
Depreciation and amortization1,588,000,0001,411,000,000
Change in deferred income taxes-1,098,000,000-959,000,000
Stock based compensation562,000,000490,000,000
Acquired in process research and development noncash7,541,000,0002,381,000,000
Other changes in operating assets and liabilities-1,899,000,000-4,419,000,000
Other operating activities net-216,000,000682,000,000
Operating cash flow27,420,000,00013,588,000,000
Capital expenditures-8,437,000,000-5,294,000,000
Purchases of noncurrent investments-862,000,000-518,000,000
Purchases of in process research and development-7,548,000,000-2,584,000,000
Cash paid for acquisitions net of cash acquired-10,692,000,000-549,000,000
Other investing activities net-72,000,000776,000,000
Investing cash flow-27,611,000,000-8,169,000,000
Dividends paid-4,635,000,000-4,039,000,000
Net change in short term borrowings0-4,338,000,000
Proceeds from issuance of long term debt8,941,000,00013,167,000,000
Repayments of long term debt-1,623,000,000-778,000,000
Share repurchases-4,334,000,000-2,600,000,000
Other financing activities net-612,000,000-746,000,000
Financing cash flow-2,263,000,000666,000,000
Effect of exchange rate changes on cash71,000,000439,000,000
Net change in cash-2,383,000,0006,524,000,000
Cash at beginning of period7,268,000,0003,268,000,000
Cash at end of period4,885,000,0009,792,000,000
Free cash flow18,983,000,0008,294,000,000

LLY trailing twelve month income statement and cash flow

Derived by AI from the figures the filings report. No filing prints these, so none of them is linked.

Twelve months ended September 30, 2026
Period start2025-10-01
Period end2026-09-30
Period typetrailing twelve months
Source accession10-Q
Income statement
Revenue86,462,000,000
Cost of sales14,150,000,000
Gross profit72,312,000,000
Research and development15,377,000,000
Marketing selling and administrative12,620,000,000
Acquired in process research and development8,070,000,000
Asset impairment restructuring and other special charges1,369,000,000
Other net expense income107,000,000
Total costs expenses and other51,693,000,000
Operating income derived34,876,000,000
Income before income taxes34,769,000,000
Income taxes7,189,000,000
Net income27,580,000,000
Gross margin %83.6%
Effective tax rate %20.7%
Net margin %31.9%
EPS diluted30.81
Cash flow
Operating cash flow30,645,000,000
Capital expenditures-10,984,000,000
Purchases of in process research and development-7,972,000,000
Cash paid for acquisitions net of cash acquired-10,804,000,000
Investing cash flow-30,414,000,000
Dividends paid-5,980,000,000
Share repurchases-5,842,000,000
Financing cash flow-5,142,000,000
Free cash flow19,661,000,000

Adjustments

Splits appliednone
ADR ration/a
FXNone. Lilly reports in U.S. dollars, and no stock split falls within the periods presented, so every figure is as filed.
Per share basisPer-share figures are per share of Lilly common stock as reported; Lilly common stock trades directly on the New York Stock Exchange and is not an ADR.

Notes

  • This record covers exactly the periods the two filings behind it put on their face: the FY2025 Form 10-K (accession 0000059478-26-000013), which presents fiscal 2025, 2024 and 2023 income statements and cash flow statements and balance sheets at December 31, 2025 and 2024; and the Form 10-Q for the quarter ended September 30, 2026 (accession 0000059478-26-000108), which presents the three and nine months ended September 30, 2026 and 2025, balance sheets at September 30, 2026 and December 31, 2025, and cash flow statements for the nine months ended September 30, 2026 and 2025.
  • All figures are stated in actual U.S. dollars. The filings present their statements in millions; every amount here has been multiplied out to whole dollars, so a $24,397 million revenue line appears as 24,397,000,000.
  • Lilly's income statement does not present an operating income subtotal. The line reported here as 'operating_income_derived' is revenue less cost of sales, research and development, marketing/selling/administrative, acquired in-process research and development, and asset impairment/restructuring/other special charges. It excludes the 'Other-net, (income) expense' line, which the company reports separately and which bridges this subtotal to income before income taxes as presented in the filings. For the September 2026 quarter that derived operating income is $8,608 million, and $202 million of other-net expense brings it to the $8,406 million of income before income taxes shown on the face of the 10-Q.
  • Only the discrete three-month periods appear in the quarterly list. The nine-month figures the 10-Q prints alongside them are reported separately under 'year_to_date' (with the prior-year nine months nested inside it), and a twelve-month view appears under 'trailing_twelve_months'.
  • The 10-Q's cash flow statement is presented on a nine-month basis only. The September 2026 and September 2025 quarterly cash flow figures shown here were obtained by subtracting the six-month amounts reported in the Form 10-Q for the quarter ended June 30, 2026 (accession 0000059478-26-000081) from the nine-month columns of the current 10-Q. Several independent checks confirm the result: the resulting quarterly stock-based compensation ($200 million in 2026, $151 million in 2025) and purchases of common stock ($377 million and $708 million) match the three-month equity tables in the current 10-Q, the September 2026 quarter's acquired in-process research and development of $4,181 million matches the income statement, and the derived cash roll-forwards land exactly on the $4,885 million (September 30, 2026) and $9,792 million (September 30, 2025) of period-end cash printed in the current 10-Q.
  • Because the six-month and nine-month columns are each rounded to the nearest million, two differenced September 2025 quarter cash flow lines differ by $1 million from the income statement: net income in the derived cash flow is $5,582 million against $5,583 million on the income statement, and the acquired in-process research and development add-back is $655 million against $656 million. The income statement figures are the reported ones.
  • Trailing-twelve-month figures are arithmetic: fiscal 2025 less the nine months ended September 30, 2025 plus the nine months ended September 30, 2026. On that basis trailing revenue is $86,462 million and trailing net income is $27,580 million.
  • Capital expenditures are the 'Purchases of property and equipment' line of the cash flow statement. The 10-Q's segment note separately discloses 'expenditures for long-lived assets' of $3,639 million for the September 2026 quarter and $8,983 million for the nine months, which additionally include computer software costs; the cash flow statement figure is used here for consistency with the free cash flow calculation.
  • Free cash flow is operating cash flow less purchases of property and equipment. It is a calculated measure, not a line item in the filings.
  • The 10-Q balance sheet presents September 30, 2026 and December 31, 2025 only, so no balance sheet is reported for the September 2025 quarter. Cash and cash equivalents at September 30, 2025 were $9,792 million per that period's comparative cash flow statement. Likewise the FY2025 10-K presents only two balance sheet dates, so fiscal 2023 carries no balance sheet here; year-end 2023 cash and cash equivalents of $2,819 million appear in the 10-K's cash flow statement.
  • Total debt is the sum of 'Short-term borrowings and current maturities of long-term debt' and 'Long-term debt' from the balance sheet: $49,503 million at September 30, 2026 against $42,503 million at December 31, 2025. The 10-Q's own liquidity discussion states total debt of $49.5 billion at September 30, 2026, an increase of $7.0 billion compared with $42.5 billion at year-end. Net debt subtracts cash and cash equivalents only; short-term investments are not broken out on the face of the balance sheet. Total liabilities is the sum of the total current and total noncurrent liabilities lines, since the balance sheet does not print a single total.
  • Dividends declared per share come from the consolidated condensed statements of shareholders' equity: $3.46 per share declared in the nine months ended September 30, 2026 and $3.00 in the nine months ended September 30, 2025. The three-month equity tables show no dividend declared in either September quarter, so no quarterly declared-per-share figure is reported. The 10-Q states that the company paid dividends of $4.6 billion, or $5.19 per share, during the nine months ended September 30, 2026, and that in October 2026 it declared a fourth-quarter 2026 dividend of $1.73 per share.
  • Goodwill rose from $5,898 million at December 31, 2025 to $9,874 million at September 30, 2026 and other intangibles from $6,521 million to $18,084 million, reflecting acquisitions completed during the year. The 10-Q states the company paid $18.2 billion during the nine months related to business development activity, primarily driven by the acquisitions of Centessa, Kelonia, AtaiBeckley, Orna, Ventyx, Curevo and Ajax, and that in October 2026 it acquired Merida for up to $2.9 billion in aggregate.
  • Lilly operates as a single reportable segment, so the product, therapeutic-area and geographic figures here are revenue disaggregations from the notes and not segment results. Because the filing rounds each figure to the nearest million, an individual product's U.S. and outside-U.S. amounts can differ by $1 million from its printed total (for example, Zepbound in the September 2026 quarter is shown as $5,267 million in the U.S. and $86 million outside the U.S. against a total of $5,352 million), and the therapeutic-area totals for the nine months sum to $67,169 million in 2026 and $45,888 million in 2025 against reported revenue of $67,170 million and $45,887 million. The totals are reproduced here exactly as the filing prints them, and the income statement figure is used as revenue.
  • The 10-Q's segment note discloses interest expense, which does not appear on the face of the income statement: $378 million for the September 2026 quarter and $1,055 million for the nine months, against $180 million and $672 million in the comparable 2025 periods.
  • Where the filing shows an em dash the amount is recorded here as zero: the net change in short-term borrowings for the nine months ended September 30, 2026 is shown as nil. Within that period, the September 2026 quarter shows a $5,284 million net reduction in short-term borrowings, offsetting the net increase recorded in the first half. All $8,941 million of 2026 long-term debt issuance and all $1,623 million of 2026 long-term debt repayments through September fell in the first half, so the September 2026 quarter shows neither.
  • Shares: the 10-Q cover reports 940,745,031 shares of common stock outstanding as of October 26, 2026, and the equity note shows 941.2 million shares at September 30, 2026.
  • Fiscal 2025, 2024 and 2023 are the three years the FY2025 10-K presents. The figures are as presented in that 10-K; the December 31, 2025 balance sheet column reprinted in the current 10-Q is identical, and neither filing reports a restatement.

Uncertainties

  • The September 2026 and September 2025 quarterly cash flow figures are derived by differencing the 10-Q's nine-month columns against the six-month amounts from the June 30, 2026 Form 10-Q (accession 0000059478-26-000081). They are arithmetic rather than figures Lilly prints. Every subtotal ties and the cross-checks described in the notes agree, but a reader wanting a company-published quarterly cash flow statement will not find one.
  • The 'operating_income_derived' line is a calculated subtotal, not a figure Lilly prints. Users who define operating income to include the 'Other-net, (income) expense' line will arrive at a different number (that alternative equals income before income taxes, since Lilly reports no interest expense line on the face of the income statement).
  • Trailing-twelve-month diluted earnings per share of $30.81 is arithmetic (fiscal 2025 less the first nine months of 2025 plus the first nine months of 2026) and is an approximation, since the share-count denominators differ across the periods being combined. No trailing share count is reported for that reason.
  • Balance sheet data are not reported for the September 2025 quarter or for fiscal 2023, because neither filing presents those columns.
  • The interim cash flow statement in the 10-Q collapses working-capital movements into a single 'Other changes in operating assets and liabilities' line, so the receivables, inventory and payables detail available annually is not available for the interim periods.
  • Free cash flow does not deduct purchases of in-process research and development ($7,548 million in the first nine months of 2026) or cash paid for acquisitions ($10,692 million), which the company classifies as investing outflows. For a business that spends this heavily on externally sourced pipeline assets, some readers will want those treated as recurring rather than discretionary.
  • The acquisitions completed during 2026 are reflected in the September 30, 2026 balance sheet but contributed only partial-period results, so period-over-period comparisons of goodwill, intangibles and acquired in-process research and development are not like-for-like.

Company details

NameELI LILLY & Co
TickerLLY
CIK0000059478
ExchangeNYSE
StateIndiana
IncorporationIndiana
SIC2834
OfficeLife Sciences
IndustryPharmaceutical Preparations

Fiscal period

Fiscal year2026
Fiscal periodQ3
TagFY26Q3
Period end2026-09-30
Form10-Q
Accession0000059478-26-000108
Fiscal year end1231
Sourcefacts

Source filings

RoleCurrentFormFiscal yearFiscal periodTagPeriod endFiledAccessionSource
annualno10-K2025FYFY252025-12-312026-02-120000059478-26-000013reported
quarterlyyes10-Q2026Q3FY26Q32026-09-302026-10-290000059478-26-000108facts

Related companies

See every covered company and its filings data.

Not investment advice, see the Disclaimer.